NORMA CHANDLER: Open Payments
NPI 1467140020 · MODESTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$757 in 29 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $122 · 2025 $757
Food & beverage: $757
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $195 |
| AstraZeneca Pharmaceuticals LP | 4 | $159 |
| Novartis Pharmaceuticals Corporation | 5 | $111 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $108 |
| Amgen Inc. | 3 | $78 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Incyte Corporation | 1 | $28 |
| CSL Behring | 1 | $21 |
Products named: NUCALA, TEZSPIRE, NEFFY, DUPIXENT, FASENRA, Rhapsido, OPZELURA, Hizentra.
Industry payments across CA — which companies pay providers there.
